177 related articles for article (PubMed ID: 37137801)
1. Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia.
Seetharaman R; Joshi SS
J Clin Lipidol; 2023; 17(3):420-421. PubMed ID: 37137801
[No Abstract] [Full Text] [Related]
2. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
3. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
Gan T; Song Y; Guo F; Qin G
Mol Biol Rep; 2022 Nov; 49(11):10915-10924. PubMed ID: 36002651
[TBL] [Abstract][Full Text] [Related]
4. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
Song J; Li X; Ni J
Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
[TBL] [Abstract][Full Text] [Related]
5. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
6. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
Shah N; Perkovic V; Kotwal S
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
[TBL] [Abstract][Full Text] [Related]
7. [SGLT2 inhibitors in diabetic and non-diabetic nephropathies].
Scheen M; Zanchi A; Martin PY; De Seigneux S
Rev Med Suisse; 2021 Feb; 17(727):378-382. PubMed ID: 33625802
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitor: 2-way superstar in nephrology?
Nangaku M
Kidney Int; 2024 Jun; 105(6):1176-1177. PubMed ID: 38777404
[No Abstract] [Full Text] [Related]
9. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
Kale A; Sharma A; Anders HJ; Gaikwad AB
Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
12. A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
Kume S; Maegawa H
J Diabetes Investig; 2022 May; 13(5):765-767. PubMed ID: 35029051
[TBL] [Abstract][Full Text] [Related]
13. Research digest: SGLT2 inhibition in kidney and liver disease.
Preiss D; Sattar N
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
[No Abstract] [Full Text] [Related]
14. Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
Yau K; Cherney DZI; van Raalte DH; Wever BE
Kidney Int; 2024 Jun; 105(6):1168-1172. PubMed ID: 38777402
[No Abstract] [Full Text] [Related]
15. SGLT2 Inhibitors and Mechanisms of Hypertension.
Briasoulis A; Al Dhaybi O; Bakris GL
Curr Cardiol Rep; 2018 Jan; 20(1):1. PubMed ID: 29349558
[TBL] [Abstract][Full Text] [Related]
16. Cardiorenal Protection in Diabetic Kidney Disease.
Lee JF; Berzan E; Sridhar VS; Odutayo A; Cherney DZI
Endocrinol Metab (Seoul); 2021 Apr; 36(2):256-269. PubMed ID: 33873265
[TBL] [Abstract][Full Text] [Related]
17. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
Packer M
J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
Davidson JA
Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors in Diabetic Kidney Disease.
Zoungas S; de Boer IH
Clin J Am Soc Nephrol; 2021 Apr; 16(4):631-633. PubMed ID: 33536241
[No Abstract] [Full Text] [Related]
20. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
